Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile

International Journal of Experimental Pathology

Volumn 90, Issue 5, 2009, Pages 489-499

  Stringer, Andrea M ^a,b,e   Gibson, Rachel J ^a,b   Bowen, Joanne M ^a,b   Logan, Richard M ^b,c   Ashton, Kimberly ^a   Yeoh, Ann S J ^a,b   Al Dasooqi, Noor ^b   Keefe, Dorothy M K ^a,b,d  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^d CANCER COUNCIL SOUTH AUSTRALIA   (Australia)

^e University of Adelaide   (Australia)

Author keywords

Bacteria; Chemotherapy; Diarrhoea; Intestinal mucosa; Mucositis

Indexed keywords

BETA GLUCURONIDASE; ELECTROLYTE; IRINOTECAN; MUCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY MASS; CELL COUNT; COLON; CONTROLLED STUDY; DIARRHEA; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION; GOBLET CELL; IMMUNOPATHOLOGY; INTESTINE FLORA; JEJUNUM; LARGE INTESTINE; MUCOSA INFLAMMATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; SMALL INTESTINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLON; DIARRHEA; FECES; FEMALE; GLUCURONIDASE; GOBLET CELLS; INTESTINAL MUCOSA; JEJUNUM; MUCINS; MUCOSITIS; RATS;

EID: 70349339546     PISSN: 09599673     EISSN: 13652613     Source Type: Journal    
DOI: 10.1111/j.1365-2613.2009.00671.x     Document Type: Article

References (25)

1. Araki E., Ishikawa M., Iigo M., Koide T., Itabashi M., Hoshi A. (1993) Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn. J. Cancer Res. 84, 697 702.
2. Armand J.P., Ducreux M., Mahjoubi M. et al. (1995) CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur. J. Cancer 31A, 1283 1287.
3. Barcelo A., Claustre J., Moro F., Chayvialle J.A., Cuber J.C., Plaisancie P. (2000) Mucin secretion is modulated by luminal factors in the isolated vascularly perfused rat colon. Gut 46, 218 224.
4. Bowen J.M., Stringer A.M., Gibson R.J., Yeoh A.S., Hannam S., Keefe D.M. (2007) VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol. Ther. 6, 1449 1454.
5. Brandi G., Dabard J., Raibaud P. et al. (2006) Intestinal microflora and digestive toxicity of irinotecan in mice. Clin. Cancer Res. 12, 1299 1307.
6. Elting L.S., Cooksley C.D., Chambers M.S., Garden A.S. (2007) Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int. J. Radiat. Oncol. Biol. Phys. 68, 1110 1120.
7. Evaldson G., Heimdahl A., Kager L., Nord C.E. (1982) The normal human anaerobic microflora. Scand. J. Infect. Dis. Suppl. 35, 9 15.
8. Geibel J.P. (2005) Secretion and absorption by colonic crypts. Annu. Rev. Physiol. 67, 471 490.
9. Gibson R.J., Bowen J.M., Inglis M.R., Cummins A.G., Keefe D.M. (2003) Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J. Gastroenterol. Hepatol. 18, 1095 1100.
10. Gibson R.J., Bowen J.M., Keefe D.M. (2005) Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int. J. Cancer 116, 464 470.
11. Gibson R.J., Stringer A.M., Bowen J.M. et al. (2007) Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats. Cancer Biol. Ther. 6, 541 547.
12. Ikuno N., Soda H., Watanabe M., Oka M. (1995) Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J. Natl. Cancer Inst. 87, 1876 1883.
13. Layton A., McKay L., Williams D., Garrett V., Gentry R., Sayler G. (2006) Development of Bacteroides 16S rRNA gene TaqMan-based real-time PCR assays for estimation of total, human, and bovine fecal pollution in water. Appl. Environ. Microbiol. 72, 4214 4224.
14. Logan R.M., Gibson R.J., Bowen J.M., Stringer A.M., Sonis S.T., Keefe D.M. (2007a) Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother. Pharmacol. 62, 33 41.
15. Logan R.M., Stringer A.M., Bowen J.M. et al. (2007b) The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat. Rev. 33, 448 460.
16. Penders J., Vink C., Driessen C., London N., Thijs C., Stobberingh E.E. (2005) Quantification of Bifidobacterium spp., Escherichia coli and Clostridium difficile in faecal samples of breast-fed and formula-fed infants by real-time PCR. FEMS Microbiol. Lett. 243, 141 147.
17. Quigley E.M. (2007) Probiotics in the management of colonic disorders. Curr. Gastroenterol. Rep. 9, 434 440.
18. Rinttila T., Kassinen A., Malinen E., Krogius L., Palva A. (2004) Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR. J. Appl. Microbiol. 97, 1166 1177.
19. Sakai H., Procop G.W., Kobayashi N. et al. (2004) Simultaneous detection of Staphylococcus aureus and coagulase-negative staphylococci in positive blood cultures by real-time PCR with two fluorescence resonance energy transfer probe sets. J. Clin. Microbiol. 42, 5739 5744.
20. Smith N.F., Figg W.D., Sparreboom A. (2006) Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro 20, 163 175.
21. Stringer A.M., Gibson R.J., Logan R.M. et al. (2007) Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Exp. Biol. Med. (Maywood) 232, 96 106.
22. Stringer A., Gibson R., Logan R., Bowen J., Yeoh A., Keefe D. (2008) Faecal microflora and β-glucuronidase expression are altered in an irinotecan-induced diarrhoea model in rats. Cancer Biol. Ther. 7, 1919 1925.
23. Takasuna K., Hagiwara T., Hirohashi M. et al. (1996) Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 56, 3752 3757.
24. Takasuna K., Hagiwara T., Watanabe K. et al. (2006) Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea. Cancer Chemother. Pharmacol. 42, 1 10.
25. Tryland I. Fiksdal L. (1998) Enzyme characteristics of beta-d-galactosidase- and beta-d-glucuronidase-positive bacteria and their interference in rapid methods for detection of waterborne coliforms and Escherichia coli. Appl. Environ. Microbiol. 64, 1018 1023.